Goldman Sachs’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History
Bought
Maintained
Sold
Other funds holding IDNA
WBG
Goldman Sachs's IDNA Position: Q3 2026 in Review
Goldman Sachs sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2026, closing a stake of 18,646 shares — an estimated $629K sold.
Goldman Sachs first reported a position in IDNA in Q4 2021 and held it in 9 quarters. The position peaked at $1.45M in Q2 2022. 81 funds tracked by Wall St. Rank hold IDNA as of Q3 2026.
- Goldman Sachs reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q3 2026 after selling out during the quarter.
- Goldman Sachs sold 18,646 iShares Genomics Immunology and Healthcare ETF shares in Q3 2026, an estimated $629K.
- Goldman Sachs first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 9 quarters.
- Goldman Sachs's iShares Genomics Immunology and Healthcare ETF position peaked at $1.45M in Q2 2022.
- 81 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.